Tyra Biosciences Announces Financial Results for Q2 2025
Tyra Biosciences, Inc. (NASDAQ: TYRA), a clinical-stage biotechnology company focused on pioneering precision medicines, has successfully dosed its first patient in the SURF302 clinical trial aimed at treating intermediate-risk non-muscle invasive bladder cancer (IR NMIBC). As of the latest report, the company maintains robust cash reserves amounting to $296.3 million, providing a financial runway through at least 2027.
CEO Todd Harris shared insight into the company's vision, stating, "We see significant opportunity to transform the treatment of bladder cancer and skeletal dysplasia by precisely targeting FGFR3. With BEACH301 open for enrollment and SURF302 advancing, we are solidifying a strong franchise with dabogratinib, which emphasizes FGFR3 selectivity and sensitivity."
Recent Developments in Clinical Trials
The second quarter of 2025 has been pivotal for Tyra Biosciences, especially regarding its lead product candidate, dabogratinib (TYRA-300). This oral FGFR3-selective inhibitor is designed to treat IR NMIBC and achondroplasia (ACH). Recent advancements include:
- Dosing in SURF302: The first patient has been treated in the SURF302 trial, an open-label Phase 2 study evaluating the efficacy and safety of dabogratinib among participants with FGFR3-altered low-grade IR NMIBC.
- BEACH301 Progress: The BEACH301 Phase 2 study aims to evaluate dabogratinib in children ages 3 to 10 with open growth plates and is currently enrolling participants.
- SURF301 Updates: Dabogratinib continues to be evaluated within Part B of SURF301, with potential regulatory considerations for future development in mUC.
- Preclinical Insights: Recent presentations showcased the favorable outcomes of dabogratinib in various preclinical models, notably improving bone growth in FGFR3-driven conditions.
Financial Overview and Future Milestones
For the second quarter, Tyra Biosciences reported:
- R&D Expenses: Recorded at $24.3 million, an increase from $18.0 million during the same period last year, primarily due to initiation costs associated with clinical trials.
- G&A Expenses: Totaling $7.1 million, increased from $5.5 million, largely reflecting personnel-related costs.
- Net Loss: The net loss amounted to $28.1 million, compared to $18.7 million in the previous year.
Future clinical milestones include the expected dosing of the first child in the BEACH301 trial in the third quarter of 2025 and the topline data from SURF302 anticipated in the first half of 2026.
A Deeper Dive into Tyra's Pipeline
Tyra Biosciences is engaged in an expansive pipeline beyond dabogratinib. The company is advancing other investigational therapies:
- TYRA-430: An oral FGFR4/3-biased inhibitor currently in a Phase 1 study, targeting advanced hepatocellular carcinoma and solid tumors linked to aberrant FGFR pathways.
- TYRA-200: An FGFR1/2/3 inhibitor demonstrating activity against FGFR2 gene alterations, currently in trial for intrahepatic cholangiocarcinoma.
- SNÅP Platform: An innovative in-house discovery platform that aids in the rapid design of targeted therapies, enabling Tyra to adapt and innovate within the precision medicine space.
About Tyra Biosciences
Tyra Biosciences, Inc. is dedicated to the innovation of precision therapies targeting key biological pathways in cancer, with a specific focus on FGFR signaling. Leveraging its proprietary SNÅP platform, Tyra aims to deliver transformative solutions in targeted oncology by anticipating and overcoming potential resistance mechanisms. Their commitment to scientific excellence is evident in their expanding pipeline of candidate therapeutics currently undergoing clinical evaluation.
Frequently Asked Questions
What are the major advancements for Tyra Biosciences in Q2 2025?
Tyra Biosciences successfully dosed its first patient in the SURF302 clinical trial and expanded its financial stability with $296.3 million in cash reserves.
What is dabogratinib?
Dabogratinib (TYRA-300) is an oral investigational FGFR3-selective inhibitor targeting bladder cancer and skeletal dysplasia, currently in ongoing clinical trials.
What financial results were reported for Q2 2025?
The company reported R&D expenses of $24.3 million, G&A expenses of $7.1 million, and a net loss of $28.1 million for the quarter.
What upcoming milestones should be noted?
Tyra expects to dose the first child in the BEACH301 trial in Q3 2025 and provide topline data from SURF302 in the first half of 2026.
How does Tyra’s SNÅP platform benefit therapeutic development?
SNÅP enhances Tyra's ability to rapidly design therapies that can effectively target and overcome resistance mechanisms in cancer treatment.
